IDH2 and astrocytoma (excluding glioblastoma): Institutional IDH-mutant astrocytomas and IDH-wild-type glioblastomas with mutations in MMR genes identified by targeted next-generation sequencing panels were subjected to a comprehensive histologic, immunohistochemical, and molecular workup.